^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Salivary Gland Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/08/2021
    Excerpt:
    SYSTEMIC THERAPY FOR SALIVARY GLAND TUMORS: Useful in Certain Circumstances...Fam-trastuzumab deruxtecan-nxki...
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Positive Breast Cancer)
    New
    Title:

    NHS Scotland Grants Trastuzmab Deruxtecan Approval for Use in Pretreated HER2+ Metastatic Breast Cancer

    Excerpt:
    The Scottish Medicines Consortium (SMC) has accepted fam-trastuzumab deruxtecan-nxki (Enhertu) as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have received 1 prior anti–HER2-based therapy....The advice is based on findings from the pivotal phase 3 DESTINY-Breast03 trial (NCT03529110), in which trastuzumab deruxtecan led to a 12-month progression-free survival (PFS) rate of 75.8%...
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Natl Compr Canc Netw
    Title:

    Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan

    Published date:
    02/01/2022
    Excerpt:
    This report describes a 67-year-old man with HER2-positive metastatic parotid gland carcinoma...After disease progression on the latter HER2-directed therapy, his malignancy demonstrated complete response to fam-trastuzumab deruxtecan, which has been sustained for the past 7 months. Fam-trastuzumab deruxtecan appears to be a well-tolerated therapeutic option in patients with HER2-positive salivary gland carcinoma...
    DOI:
    10.6004/jnccn.2021.7089